Virtual Library
Start Your Search
X. Si
Author of
-
+
P2.03 - Chemotherapy/Targeted Therapy (ID 704)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.03-041 - The Concentration of Avitinib in Cerebrospinal Fluid and Its Efficacy and Safety in NSCLC Patients with T790M Mutation (ID 9458)
09:30 - 09:30 | Author(s): X. Si
- Abstract
Background:
Avitinib is an oral, potent, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor selective for T790M resistance mutations. We report the safety, the intracranial/extracranial efficacy, and the blood brain barrier (BBB) penetration rate of Avitinib in non-small cell lung cancer(NSCLC) patients with EGFR T790m mutation. The data come from Peking Union Medical College hospital-a single center of the Phase 1, open-label, multicenter study (NCT02330367).
Method:
NSCLC Patients with acquired EGFR T790m (+) were enrolled. Patients were orally administered with dose escalating from 150 mg to 300 mg twice daily for 28-continuous-day cycles until disease progression. Blood (2mL) and cerebrospinal fluid (CSF) samples (2ml) were collected for concentration analysis on day 29 in available patients with brain metastases (BM). Tumor response was assessed on day 29 and then every 8 weeks.
Result:
Sixteen patients were included. Nine patients had asymptomatic BM, and all the nine patients had more than 3 BM lesions. The most frequent adverse events were the elevated hepatic transaminases (10/16, 62.5%) and diarrhea (5/16, 31.3%), Most were mild and reversible. 9 Patients (56.3%) achieved Partial Response (PR), 6 (37.5%) achieved Stable Disease (SD). Median Progress Free Survival (PFS) was 247 days (95%CI: 154.8-339.2), and the Median Overall Survival (OS) was 536 days (95%CI: 363.6-708.4). Of the 7 evaluable BM patients, the median intracranial PFS was 142 days (95% CI 31.1-252.9), with two patients progressed first in intracranial disease, while five patients had concurrent intracranial and extracranial progression after avitinib treatment. The cytologic analysis of CSF showed one meningeal metastases who accepted intrathecal injection with methotrexate and dexamethasone later. The blood and CSF analysis of 5 BM patients showed the BBB penetration rate were 0.046%-0.146% (Table).
[1]Her BBB was broken by postocular metasatses. [2]He accepted brain radiotherapy before avitinib, and he also accepted chemotherapy with pemetrexed plus carboplatin plus endostatin after progression from avitinib. He was excluded from the analysis of intracranial PFS.patients CSF Con. (ng/ml) Plasma Con. (ng/ml) Per.% Intracranial PFS (days) Extracranial PFS (days) 1 0.106 231 0.046 566 566 2 0.425 291 0.146 60 177 3 0.487 631 0.077 142 142 4 4.05 2940 0.138 138 138 5 1.72 1890 0.091 28 28 6 24 227 10.6[1] 218 218 7 308 350 8 550[2] 252
Conclusion:
Avitinib is well tolerated and efficacious in EGFR T790m(+) NSCLC patients. Its concentration in CSF is low, and the penetrability of BBB is weak. The median intracranial PFS for asymptomatic BM is relative short comparing to extracranial disease. Further studies are proceeding.
